New cholesterol combo drug shows promise in early trial
NCT ID NCT06742853
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called AZD0780 in 81 healthy adults with high cholesterol. Participants received AZD0780 alongside other cholesterol-lowering medicines like ezetimibe, rosuvastatin, or bempedoic acid. The goal was to see how well the combination lowers LDL (bad) cholesterol and whether it is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0780 (a drug to lower cholesterol) combined with ezetimibe, rosuvastatin, or bempedoic acid
What this could lead to
If successful, this could point toward a new combination treatment to lower high cholesterol more effectively.
What could go wrong
This is an early Phase 1 trial with only 81 people, so results may not apply to everyone. The drug may cause side effects or not work as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Glendale, California, 91206, United States
-
Research Site
Brooklyn, Maryland, 21225, United States
-
Research Site
Harrow, HA1 3UJ, United Kingdom